CardioNerds

DocwireNews

The following article was written by Dr. Alaa Diab as a CardioNerds Conference Scholar for <a href="https://www.aspconline.org/">The American Society for Preventive Cardiology 2022 Congress on Cardiovascular Disease Prevention</a>.
Type 2 diabetes mellitus is becoming more prevalent in the United States, with an estimate of 37.3 million Americans living with diabetes according to the 2020 CDC statistics. What’s worrisome about this data? Adults with diabetes are at a greater risk of developing cardiovascular disease (CVD) with rates 2 to 4 times higher than in adults without diabetes.1 In addition patients with diabetes have a 1.8 to 6-fold greater risk of stroke.2 Given the increasing prevalence of diabetes and its inherent CVD risks, we must ask: how are we managing diabetes to prevent CVD, and most importantly how to eliminate disparities in diabetes care?
The STENO-2 study enrolled 160 patients with type 2 diabetes with signs of kidney disease (microalbuminuria) in Denmark and randomly assigned them to either receiving intensive therapy (i.e., tight glucose regulation with the use of renin–angiotensin system blockers, aspirin, and lipid-lowering agents) or conventional diabetic therapy.3 The primary endpoint was time to death from any cause and secondary end points were death from CVD causes and CVD comorbidities, such as stoke and myocardial infarction.
Over a mean follow-up of 13.3 years, 24 patients (30%) in the intensive therapy group died in comparison to 40 patients (50%) in the conventional therapy group, meaning that there was an absolute risk reduction of 20% (P=0.02).3 Intensive therapy was associated with a lower risk of death from cardiovascular causes (hazard ratio, 0.43; 95% CI, 0.19 to 0.94; P=0.04) and of cardiovascular events (hazard ratio, 0.41; 95% CI, 0.25 to 0.67; P&lt;0.001).3 Nowadays, there are more potent drugs for managing diabetes towards CVD prevention, such as the SGLT2-Inhibitors and GLP1-Receptor Agonists.
Erin Michos, MD, MHS Associate Professor of Medicine and Epidemiology in the Department of Medicine and Director of Women&#8217;s Cardiovascular Health at the Johns Hopkins School of Medicine highlighted the importance of eliminating disparities in diabetes care at the ASPC 2022. “Disparities exist in their utilization by race, ethnicity, and socioeconomic status, may contribute to worse morbidity and mortality in these populations” said Dr. Michos. “Addressing such disparities will require a multipronged approach; we must address Social Determinants of Health, optimize self-management by free diabetes classes, remove barriers for new therapies by eliminating prior authorizations for diabetic patients, and educate the underrepresented populations on the risk of complications” she added.
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Key points on management of Diabetes towards CVD prevention: by Dr. <a href="https://twitter.com/ErinMichos?ref_src=twsrc%5Etfw">@ErinMichos</a> <a href="https://twitter.com/CardioNerds?ref_src=twsrc%5Etfw">@CardioNerds</a> <a href="https://twitter.com/hashtag/ASPC2022?src=hash&amp;ref_src=twsrc%5Etfw">#ASPC2022</a> <a href="https://twitter.com/DeveshRaiMD?ref_src=twsrc%5Etfw">@DeveshRaiMD</a> <a href="https://twitter.com/KahtanAlfadhl?ref_src=twsrc%5Etfw">@KahtanAlfadhl</a> <a href="https://t.co/SX8Xr5Ry2W">pic.twitter.com/SX8Xr5Ry2W</a>
&mdash; Alaa Diab, MD MPH (@DrAlaaDiab) <a href="https://twitter.com/DrAlaaDiab/status/1553412364166467584?ref_src=twsrc%5Etfw">July 30, 2022</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
&nbsp;
Diabetic care is being held up at the stop signs on the prevention highway. The road to reducing diabetes-associated CVD morbidity, mortality, and health inequalities is clear if we stand together with a multifaceted systems approach to address known barriers.
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
The rate of CV death is increased by 50% in those with diabetes&#8211; Dr. <a href="https://twitter.com/ErinMichos?ref_src=twsrc%5Etfw">@ErinMichos</a> at <a href="https://twitter.com/hashtag/ASPC2022?src=hash&amp;ref_src=twsrc%5Etfw">#ASPC2022</a>
So how do we individualize diabetes management❓
 <a href="https://twitter.com/CardioNerds?ref_src=twsrc%5Etfw">@CardioNerds</a> <a href="https://twitter.com/DeveshRaiMD?ref_src=twsrc%5Etfw">@DeveshRaiMD</a> <a href="https://twitter.com/KahtanAlfadhl?ref_src=twsrc%5Etfw">@KahtanAlfadhl</a> <a href="https://twitter.com/hashtag/diabetes?src=hash&amp;ref_src=twsrc%5Etfw">#diabetes</a> <a href="https://twitter.com/hashtag/MedTwitter?src=hash&amp;ref_src=twsrc%5Etfw">#MedTwitter</a> <a href="https://twitter.com/DrMarthaGulati?ref_src=twsrc%5Etfw">@DrMarthaGulati</a> <a href="https://t.co/tSWlaJOEIR">pic.twitter.com/tSWlaJOEIR</a>
&mdash; Alaa Diab, MD MPH (@DrAlaaDiab) <a href="https://twitter.com/DrAlaaDiab/status/1553411773658693632?ref_src=twsrc%5Etfw">July 30, 2022</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Overcoming Barriers in the Treatment of Diabetes by Dr. <a href="https://twitter.com/ErinMichos?ref_src=twsrc%5Etfw">@ErinMichos</a> DM increases the risk of CVD in both <a href="https://twitter.com/hashtag/men?src=hash&amp;ref_src=twsrc%5Etfw">#men</a> &amp; <a href="https://twitter.com/hashtag/women?src=hash&amp;ref_src=twsrc%5Etfw">#women</a> with DM have almost as much risk of CVD as <a href="https://twitter.com/hashtag/Multifaceted?src=hash&amp;ref_src=twsrc%5Etfw">#Multifaceted</a> care is required with diabetes and elevated CVD risk <a href="https://twitter.com/hashtag/ASPC2022?src=hash&amp;ref_src=twsrc%5Etfw">#ASPC2022</a> <a href="https://twitter.com/a_l_bailey?ref_src=twsrc%5Etfw">@a_l_bailey</a> <a href="https://twitter.com/DrAlaaDiab?ref_src=twsrc%5Etfw">@DrAlaaDiab</a> <a href="https://twitter.com/CardioNerds?ref_src=twsrc%5Etfw">@CardioNerds</a> <a href="https://t.co/okpuMReehn">pic.twitter.com/okpuMReehn</a>
&mdash; Kahtan Fadah (@KahtanAlfadhl) <a href="https://twitter.com/KahtanAlfadhl/status/1553410659190296578?ref_src=twsrc%5Etfw">July 30, 2022</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
References:
<ol>
<li>Raghavan S, Vassy JL, Ho YL, et al. Diabetes Mellitus-Related All-Cause and Cardiovascular Mortality in a National Cohort of Adults. J Am Heart Assoc. 2019;8(4):e011295. doi:10.1161/JAHA.118.011295</li>
<li>Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in Stroke. 2011 Feb;42(2):e26]. Stroke. 2011;42(2):517-584. doi:10.1161/STR.0b013e3181fcb238</li>
<li>Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-591. doi:10.1056/NEJMoa0706245</li>
</ol>

Emily Menendez

Gemcitabine and Cisplatin +/- Nab-Paclitaxel for Newly Diagnosed BTC: Results From SWOG S1815

Bile Duct Cancer

Rob Dillard

Novel Tool is Effective at Predicting the Onset of Mild Cognitive Impairment and Alzheimer Dementia

Dementia

Laura Litwin

Adding Amivantamab to Chemotherapy Shows OS Benefit for Certain Patients With NSCLC

EGFR+ NSCLC

Latest News

Diabetic Care Held Up at Stop Signs on the Prevention Highway

Cardionerds is an entertaining and educational medical cardiology podcast created by three cardiologists. They want to bring high yield cardiovascular concepts in a fun and engaging format for their listeners of all levels. Click below to learn more!

The following article was written by Dr. Alaa Diab as a CardioNerds Conference Scholar for The American Society for Preventive Cardiology 2022 Congress on Cardiovascular ...

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe